Buying ZS Pharma Could Give AstraZeneca Best-In-Class Blockbuster

Buying California-based ZS Pharma for $2.7bn gives AstraZeneca PLC a potential blockbuster already by next year, adds substance to the pure pharma's offerings for cardiovascular and metabolic disease, and should support its return to growth strategy.